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Abstract 
Hapten heterology was introduced into the steps of hybridoma selection for the development 
of monoclonal antibodies (MAbs) against deoxynivalenol (DON). Firstly, a novel heterologous 
DON hapten was synthesized and covalently coupled to proteins (i.e., bovine serum albumin 
(BSA), ovalbumin and horseradish peroxidase) using the linkage of cyanuric chloride (CC). 
After immunization, antisera from different DON immunogens were checked for the presence of 
useful antibodies. Next, both homologous and heterologous enzyme-linked immunosorbent assays 
(ELISAs) were conducted to screen for hybridomas. It was found that heterologous screening could 
significantly reduce the proportion of false positives and appeared to be an efficient approach 
for selecting hybridomas of interest. This strategy resulted in two kinds of broad-selective 
MAbs against DON and its analogues. They were quite distinct from other reported DON-
antibodies in their cross-reactivity profiles. A unique MAb 13H1 derived from DON-CC-BSA 
immunogen could recognize DON and its analogues in the order of HT-2 toxin > 15-acetyl-
DON > DON > nivalenol, with IC50 ranging from 1.14 to 7.69 µg/mL. Another preferable 
MAb 10H10 generated from DON-BSA immunogen manifested relatively similar affinity to 
DON, 3-acetyl-DON and 15-acetyl-DON, with IC50 values of 22, 15 and 34 ng/mL, 
respectively. This is the first broad-specific MAb against DON and its two acetylated forms 
and thus it can be used for simultaneous detection of the three mycotoxins. 
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 1. Introduction 
Monoclonal antibodies (MAbs) are powerful biological tools for the modern analytical sciences. Until 
now, hybridoma technology is still the most common method for MAb development, in which 
hybridoma screening is a key step to select high-affinity MAbs but rather a labor-intensive and 
time-consuming process. An ideal screening method should be fast, reliable and easy to 
accomplish. For generating MAbs against low-molecular-weight analytes (haptens, e.g., 
pesticides, antibiotics and mycotoxins), one of the traditional methods for hybridoma screening is 
homologous indirect enzyme-linked immunosorbent assay (ELISA), i.e. the coating hapten is the 
same as the immunizing hapten. However, through this way, a high proportion of false 
positives are frequently encountered (Cervino et al., 2008). The problem can be associated 
with the fact that many of the initially selected positive clones could have strong affinity to the 
spacer arms or the whole hapten-arm regions, which led to poor or even no inhibition by the 
free target compounds (Kim et al., 2003). Since hapten heterology is often employed to 
modify the performance of competitive immunoassay for small molecules (Kim et al., 2003; 
Wang et al., 2011), it can also be introduced into the steps of hybridoma selection. To date, 
using heterologous ELISAs for hybridoma screening is yet limited to very few kinds of MAb 
generation (Liu et al., 2010; Muldoon et al., 2000; Shim et al., 2010; Wang et al., 2010). 
Hence, in the present study, we attempted to explore the applicability of heterologous screening for 
hybridoma selection.  
Deoxynivalenol (DON; vomitoxin) was the molecule of interest, given that it is a prevalent 
trichothecene mycotoxin that contaminates cereal-based food and feed. So far, all the 
previously reported DON-MAbs were selected by homologous screening and most of them 
displayed much higher affinity either to 3-acetyl-DON (3-ADON) (Baumgartner et al., 2010; 
Casale et al., 1988; Maragos and McCormick, 2000; Tangni et al., 2010) or to 15-acetyl-DON 
(15-ADON) (Dos Santos et al., 2011; Maragos et al., 2011; Nicol et al., 1993; Sinha et al., 
1995; Xu et al., 2010), the two derivatives that often co-occur with DON. Thus, the relevant 
immunoassays could only be used to screen for DON/3-ADON or DON/15-ADON, not three 
of them simultaneously. In 2010 health authorities considered the toxicity of the acetylated 
derivatives equal to that of DON (JECFA, 2010), but a recent study suggested the higher 
toxicity of 15-ADON should be taken into account (Pinton et al., 2012). Moreover, DON-3-
glucoside (DON-3-G), another DON masked form detected in cereals and beers, also has non-
negligible contribution to the overall DON contamination (Berthiller et al., 2009), though the 
toxicology data are insufficient. Therefore, it is necessary to develop generic or broad-specific 
(broad-selective) MAbs with similar affinity to DON and its analogues of concern, so as to 
rapidly determine the sum of these mycotoxins in a single test and assess the health risk from 
“total” DON exposure.  
In the current work, a new heterologous DON hapten was introduced for immunization and 
hybridoma screening. Results indicated that MAbs selected by the heterologous ELISAs were broad-
selective to DON and its analogues, which were different from other previous DON-antibodies. 
To the best of our knowledge, it is the first report to employ hapten heterology for hybridoma 
screening to produce broad-specific MAbs against DON and its analogues.  
2. Materials and methods  
2.1. Reagents and materials  
DON, 3-ADON and 15-ADON standards were obtained from Fermentek (Jerusalem, Israel). 
Other mycotoxin reference standards namely nivalenol (NIV), HT-2 toxin, T-2 toxin, 
fusarenon-X (FUS-X) and the de-epoxy metabolite of DON (DOM) were purchased from 
Sigma-Aldrich (Bornem, Belgium), except that DON-3-G was from Biopure 
Referenzsubstanzen GmbH (Tulln, Austria). Figure 1 lists the chemical structures of related 
compounds used in this work.  
Figure 1 Chemical structures of DON and its related analogues 
Colorburst™ blue 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution containing 
hydrogen peroxide was supplied by Alerchek (Springvale, Maine, USA). Rabbit anti-mouse 
immunoglobulins (anti-mouse IgG secondary antibody; protein concentration of 2.5 g/L) were 
purchased from DakoCytomation (Glostrup, Denmark). Bovine serum albumin (BSA), 
ovalbumin (OVA), horseradish peroxidase (HRP), 1,1-carbonyldiimidazole, cyanuric 
chloride, N,N’-diisopropylethylamine, rabbit anti-mouse IgG secondary antibody labeled with 
HRP (SecAb-HRP), phosphate buffered saline (PBS, 0.01 M, pH 7.4) tablet, carbonate 
buffered saline (CBS, 0.05 M, pH 9.6) capsule, complete and incomplete Freund’s adjuvants, 
Tween 20 and skim milk powder were obtained from Sigma-Aldrich (Bornem, Belgium). 
Deionized water was purified by a Millipore Milli-Q system (Molsheim, France). Other 
chemicals and solvents were of analytical grade and bought from VWR International (Leuven, 
Belgium).  
Nunc-Immuno™ F96-well microplates and Nunclon™ cell culture plates were from Nalge Nunc 
International (Roskilde, Denmark). Protein concentrators (9K MWCO, 20 mL) were purchased 
from Thermo Scientific (Rockford, USA).  
2.2. Preparation of DON-protein conjugates 
A highly reactive agent, cyanuric chloride (CC), was used to make a new heterologous hapten 
derivative for DON. The DON-CC-BSA conjugate was prepared in a two-step procedure 
based on previous publications (Abuchowski et al., 1977; Abuknesha and Griffith, 2005). 
Briefly, a solution of DON (7 mg) in cold acetonitrile (3.5 mL) was added to a vigorously 
stirred solution of cyanuric chloride (4.4 mg) in acetonitrile (9 mL) cooled to -20 °C for 1h. 
Afterwards, a solution of N, N’-diisopropylethylamine (6.1 mg) in ice-cold acetone (1.8 mL) 
was added. The mixture was kept at 55-60 °C for 5 h and then it was allowed to mix for 
another 16 h at room temperature. The product was evaporated to dryness at 40 °C under a 
stream of nitrogen, followed by adding a solution of 3.6 mg of BSA in 2 mL of 0.1 M sodium 
tetraborate (pH 9.2) and stirring for 1 h at 4 °C. The resultant DON-CC-BSA conjugate was 
purified by dialyzing extensively with PBS and concentrated using a protein concentrator (9K 
MWCO, 20 mL). Likewise, the same method was used for preparing DON-CC-OVA and 
DON-CC-HRP conjugates. Additionally, a common DON-BSA conjugate was synthesized by 
the 1, 1-carbonyldiimidazole coupling reaction, adopted from published literatures (Maragos 
and McCormick, 2000; Xiao et al., 1995), as well as DON-OVA and DON-HRP probes. Both 
DON-CC-protein and DON-protein could be the mixtures of conjugates linked either at the C-
3, the C-15, or even both. Figure 2 presents the structures of the two types of DON-protein 
conjugates. The protein concentrations of conjugates were determined with bicinchoninic acid 
using a commercial test kit (Pierce, Rockford, IL, USA).  
Figure 2 Structures of DON-protein conjugates 
2.3. Immunization and cell fusion 
BALB/c female mice (6-8 weeks old) were immunized with DON-CC-BSA or DON-BSA 
conjugate. For each mouse, the volume of injection was 200 µL every time. The first dose 
consisted of 100 µg of the conjugate per mouse, which was subcutaneously injected as an 
emulsion of PBS and complete Freund’s adjuvant. Two subsequent boosts were given 
intraperitoneally at 3-week intervals, with the same amount of immunogen emulsified by 
incomplete Freund’s adjuvant. Afterwards, identical injections were given at 1-month 
intervals and one week after each boost, mice were tail-bled and titers of antisera were 
measured by indirect ELISA to determine whether additional immunizations would be 
necessary prior to cell fusion. After a resting period of at least 3 weeks from the last injection 
in adjuvant, mice selected to be spleen donors for hybridoma production received a final 
intraperitoneal injection of 100 µg of the conjugate dissolved in PBS (without adjuvant). 
Three days after the final injection, cell fusion was performed according to standard 
procedures and some details were previously described (Burmistrova et al., 2009). 
2.4. Hybridoma selection and subcloning 
Ten to twelve days after cell fusion, plates of hybridoma culture supernatants were initially 
screened by non-competitive indirect or direct ELISAs, based on homologous or heterologous 
DON antigens. The positive wells were picked out and screened again by competitive 
ELISAs. Only those wells that gave substantial inhibition (more than 20%) by DON and had 
no cross-reactivity with OVA were selected. The interesting hybridomas were expanded, 
rechecked and subcloned by limiting dilution for 2-3 cycles to ensure the monoclonality. The 
resulting stable clones were expanded and stored in liquid nitrogen. For large-scale production 
of MAbs, each cell-line was cultured in a two-compartment bioreactor CELLine 350 
(INTEGRA Biosciences AG, Zizers, Switzerland) for more than three months. The collected 
supernatant was further used for MAb characterization. 
2.5. Indirect ELISA  
All incubations except for the first coating step were carried out at 37 °C, and after each 
incubation, the plates were washed three times (300 µL/well) with PBST (PBS containing 
0.05 % Tween 20) using an automatic microplate washer “96PW” (TECAN, Salzburg, 
Austria). High-binding polystyrene 96-well microplates were coated with DON-CC-OVA or 
DON-OVA diluted in CBS (100 μL/well). After incubation at 4 °C overnight, the plates were 
blocked with 2% skim milk in PBS (300 μL/well) for 30 min. For competitive indirect ELISA 
analysis, standard solutions of DON and PBS control were added (50 μL/well), followed by 
adding 50 μL/well of diluted antibodies (antisera or culture supernatants) in PBS. After 
shaking and incubation for 1h, 100 μL/well of SecAb-HRP was added and incubated for 
another 1 h. Then, 100 μL/well of TMB substrate solution was added. The reaction was 
stopped after 15 min with 2 M sulphuric acid (50 μL/well), and the absorbance at 450 nm was 
measured by a Bio-Rad model 550 microplate reader (Richmond, CA, USA). 
2.6. Direct ELISA  
The microplates were coated with 100 μL/well of anti-mouse IgG secondary antibody diluted 
in CBS (5 μg/mL) by an overnight incubation at 4 °C. Then, the plates were blocked in the 
same above-mentioned way. For testing, antibodies diluted in PBS were added (100 μL/well). 
After 1 h incubation and the washing step, standard solutions of DON and PBS control were 
added (50 μL/well), followed by adding another 50 μL/well of DON-CC-HRP or DON-HRP 
diluted in PBS. The plates were shaken and incubated for another 1 h, and color development 
was carried out as described in the procedure of indirect ELISA.  
2.7. Assay sensitivity test 
Checkerboard assays, in which antibodies were titrated against various amounts of coating 
antigens or enzyme tracers, were conducted to select appropriate working concentrations for 
evaluation of assay sensitivities to DON. Standard competitive curves were obtained by 
plotting relative absorbance (ratio of absorbance measured at the standard concentration and 
zero concentration: B/B0×100%) against the logarithm of analyte concentration. Sigmoid 
curves were simulated by means of Origin 8.0 software. From the equations, IC50 values (i.e., 
analyte concentrations at which the maximum absorbances were inhibited by 50%) were 
determined to assess the assay sensitivity. 
2.8. Cross-reactivity study 
To evaluate MAb specificity or assay selectivity, a set of DON analogues were utilized to 
perform cross-reactivity studies. IC50 of each tested compound was based on its corresponding 
competitive curve. Cross-reactivity (CR) values were calculated according to the following 
equation: CR(%) = [IC50 (DON) / IC50 (analogue)]×100%，where CR values were 
calculated using IC50 values with units of µg/mL. Likewise, CRmolar values were calculated 
using IC50 molar values with units of nmol/mL (Xu et al., 2009).  
3. Results and discussion 
3.1. Immune response to DON immunogens 
As mentioned above, most of existing DON-MAbs have much higher affinity either to 3-
ADON or to 15-ADON, because the reported DON immunogens often contain the ester-based 
linkages at the C-3 or the C-15 of DON, which resemble the acetyl groups of 3-ADON or 15-
ADON. Therefore, in our initial study, we attempted to employ a totally different linker for 
making DON-protein conjugates. Using cyanuric chloride (CC) to form a spacer arm, DON 
was successfully coupled to proteins. Mice injected with DON-CC-BSA developed very high 
immune responses. After the third boost, the antiserum titers were higher than 10,000 with 
DON-CC-OVA as coating antigen. Table 1 lists the polyclonal antibody characteristics from 
the best DON-CC-BSA mouse. Judged from the working concentration of antigen and 
antiserum, it is clear that the polyclonal antibody had much higher affinity to the homologous 
hapten DON-CC, suggesting the strong recognition of both DON and the CC bridge region. 
But concerning the inhibition results, the DON-OVA coated ELISA was more sensitive to 
DON, which proved that the heterologous format did improve the assay sensitivity for DON.  
Table 1 Characteristics of antisera from the best DON-CC-BSA and DON-BSA mice 
Immunogen ELISA format Serum dilution Coating antigen 
(µg/mL) 
Maxium 
absorbance  
Inhibition by  
2 µg/mL DON DON-CC-BSA Homologous 1/16,000 DON-CC-OVA (1) 0.96 11.2% 
DON-CC-BSA Heterologous 1/4,000 DON-OVA (4) 0.92 34.8% 
DON-BSA Homologous 1/16,000 DON-OVA (0.5) 0.88 57.9% 
DON-BSA Heterologous 1/16,000 DON-CC-OVA (4) 0.81 54.5% 
 
Meanwhile, immunization with the usual DON-BSA was implemented for comparison. The 
produced antisera could recognize both DON-OVA and DON-CC-OVA very well, despite 
that the dose of DON-CC-OVA was higher than that of DON-OVA (see Table 1). However, 
using the heterologous coating antigen did not promote the assay sensitivity for DON. By 
contrast, the polyclonal antibody derived from DON-BSA displayed stronger affinity to the 
free DON than that from DON-CC-BSA. The phenomena must be associated with the fact 
that DON-BSA contained a smaller linkage compared to DON-CC-BSA, leading to the 
reduced influence from the spacer arm. Given that the molecular weight of DON is less than 
300 Da, the influence of the linkage arm is indeed crucial (Chappey et al., 1994).  
3.2. Hybridoma screening by indirect ELISA 
The best DON-CC-BSA mouse was first sacrificed for hybridoma production. Due to a great 
amount of spleen cells, seventeen 96-well plates were used to distribute the fused cell 
suspension. Non-competitive indirect ELISAs based on both DON-CC-OVA and DON-OVA 
were used for primary hybridoma screening. When using DON-CC-OVA (4 µg/mL) for 
homologous screening, almost all the wells were visually positive. This could be envisaged 
from the very high titer of antiserum and the satisfying fusion rate (every well contained at 
least one cluster of hybridomas). Whereas, using DON-OVA (8 µg/mL) for heterologous 
screening, only a few wells in each plate manifested strong signals. These wells showed even 
deeper color in the corresponding DON-CC-OVA-coated plate. In other words, these double-
checked positive wells exhibited higher affinity to the DON part than other wells did. By 
contrast, it seemed that a lot of hybridomas could secrete antibodies to recognize the whole 
DON-CC structure or the CC linker, which led to the high background of DON-CC-OVA-
coated ELISA, as the CC ring structure is also an important epitope for eliciting the immune 
response.  
In total, 47 positive wells were quickly selected based on the results of DON-OVA-coated 
heterologous ELISA. After adding the fresh medium overnight, they were rechecked by the 
competitive indirect ELISA. Top 6 wells with both strong signal and substantial inhibition by 
DON were expanded and re-selected. Eventually, the best clone 13H1 was subjected to 
subcloning for three cycles to get a stable single-cell line.  
3.3. Hybridoma screening by direct ELISA 
  Since the antiserum titer of the DON-BSA mice was considerably high, it could be foreseen 
that a great number of positive clones would be obtained when using indirect ELISA with 
DON-OVA for hybridoma screening. Moreover, the standard indirect ELISA screening can 
result in a large number of false positives, which give rise to a lot of unnecessary workload 
(Cervino et al., 2008)  and exorbitant waste of the precious experimental materials in the 
following procedures. With the aim to efficiently select the target clones that can secrete high-
affinity MAbs, direct ELISA was applied to screen hybridomas from the DON-BSA mice, 
although the sensitivity of direct ELISA was not as high as that of indirect ELISA (Cervino et 
al., 2008). However, from another point of view, only clones with high affinity to the target 
antigen should be detected as the positives by direct ELISA, reducing the number of clones 
with fairly low affinity. 
  For initial screening of DON-BSA hybridomas, non-competitive direct ELISAs based on 
both DON-HRP and DON-CC-HRP were carried out. Likewise, much more positive wells 
were found when using the homologous tracer DON-HRP, compared to the case of using the 
heterologous tracer DON-CC-HRP. The wells, which were positive from DON-CC-HRP-
based ELISA, gave even stronger signals in the corresponding DON-HRP-based ELISA. 
Thus, the top 8 positive wells were easily chosen for further inhibition tests by competitive 
direct ELISA. Among them, two clones 10H10 and 14D4 could recognize free DON very 
well and exhibited cross-reactivity to both 3-ADON and 15-ADON; another clone 4B10 had 
much higher affinity to 3-ADON but very poor reactivity to DON. Subsequently, hybridomas 
10H10 and 14D4 were subcloned to obtain the final stable single-cell lines. Given that these 
two MAbs possessed very similar characteristics, only clone10H10 was used for large-scale 
culturing. 
To be emphasized, the advantage of heterologous screening is that it can notably reduce 
the proportion of false positives, and hence one may efficiently get the interesting hybridomas 
with high affinity to the free target analyte. Consequently, it generates time-saving and 
is labor-saving as well as being cost-effective.  
3.4. Assessment of assay sensitivity to DON 
The two representative clones 13H1 and 10H10 were individually cultured in CELLine 
350 bioreactors for large-scale production of MAbs. In view of practical applications, the 
competitive direct ELISA format, a popular format in commercial ELISA kits, was used for 
MAb characterization. After checkerboard titration, the standard curves were set up with the 
optimal working dilutions of MAbs and tracers. As shown in Figure 3, for clone 13H1, the 
heterologous format based on DON-HRP did improve the assay sensitivity to DON, with IC50 
value decreasing from 4.34 µg/mL (DON-CC-HRP-traced ELISA) to 2.13 µg/mL (DON-
HRP-traced ELISA). Whereas, for clone 10H10, the heterologous format based on DON-CC-
HRP was rather less sensitive (IC50 = 0.064 µg/mL) than the homologous format based on 
DON-HRP (IC50 = 0.022 µg/mL). These results confirmed that the degree of hapten 
heterology could influence the assay sensitivity of direct competitive ELISA, but whether 
improving or not, it depends on the specific case. The assay sensitivity may not be in parallel 
with the degree of hapten heterology, and this finding is similar to that of Wang et al. (Wang 
et al., 2011). Additionally, ELISAs based on clone 10H10 showed much higher sensitivity to 
DON than those from clone 13H1 (differences of two orders of magnitude), which could be 
foreseen from the primary results of antisera above-mentioned. 
Figure 3 Standard curves of direct competitive ELISAs based on different MAbs and tracers (n=6). 
B/B0: ratio of absorbance measured at the standard concentration and zero concentration. 
3.5. Assay selectivity  
The selectivity of immunoassay is mainly based on the specificity of the involved antibody. 
In this work, DON-HRP-traced competitive direct ELISA was also used for cross-reactivity 
measurement, including eight common DON analogues (see Figure 1) for tests. Table 2 lists 
the cross-reaction results of MAbs 13H1 and 10H10.  
  
Table 2 Cross-reaction results of MAbs 13H1 and 10H10 
Compound MW 
Clone 13H1  Clone 10H10 
IC50,  
µg/mL 
CR,
%   
IC50 molar, 
nmol/L 
CRmolar, 
% 
  IC50,  
µg/mL 
CR,  
% 
IC50 molar, 
nmol/L 
CRmolar
, % 
DON 296 2.13 100 7.20  100   0.022 100  0.074  100 
3-ADON 338 34.12 6 100.95  7   0.015 147  0.044  167 
15-ADON 338 1.62 131 4.79  150   0.034 65  0.101  74 
NIV 312 7.69 28 24.65  29   > 10 < 0.2 > 32 < 0.2 
T-2 toxin 466 > 100 < 2 > 214.6 < 3   > 10 < 0.2 > 21 < 0.3 
HT-2 toxin 424 1.14 187 2.69 268   > 10 < 0.2 > 24 < 0.3 
FUS-X 354 > 100 < 2  > 282.5 < 3   > 10 < 0.2 > 28 < 0.3 
DON-3-G 458 15.67 14 34.21 21   0.072 31  0.157  47 
DOM 280 5.47 39 19.54 37   0.079 28  0.282  26 
 
It seemed that the clone 13H1 could be considered as a unique broad-selective antibody, 
with even higher sensitivity to HT-2 toxin and 15-ADON than to DON, minor affinity toward 
NIV, DOM and DON-3-G, and very low cross-reactivity against 3-ADON, while no obvious 
cross-reaction with T-2 toxin and FUS-X was found. Interestingly, this MAb could recognize 
HT-2 toxin but not T-2 toxin, as both of them belong to type A trichothecene (absence of a 
carbonyl at the C-8) and just differ from the C-4. The observations were mainly ascribed to 
the immunogen DON-CC-BSA, in which the CC linker must be located more at the C-15 than 
at the C-3 and it significantly affected the electronic configuration of the DON molecule. 
Probably, the molecular property of the immunizing hapten DON-CC was more close to HT-2 
toxin than to other tested compounds, which led to the fact that the generated antibody had the 
greatest affinity to HT-2 toxin. These results were in agreement with Muldoon et al.’s 
perspective that both steric and electronic features governed antibody recognition (Muldoon et 
al., 2000).  
MAb of clone 10H10 gave better sensitivity to 3-ADON than to DON, moderate affinity 
to 15-ADON, and minor cross-reactions with DON-3-G and DOM, but no cross-reactivity 
toward the other trichothecenes. It was interesting to observe that this anti-DON MAb could 
recognize both 3-ADON (IC50 = 0.015 µg/mL) and 15-ADON (IC50 = 0.034 µg/mL) very 
well, and the differences among the three CR values were much smaller than those from other 
reported anti-DON MAb-based ELISAs (Li et al., 2012; Maragos et al., 2006; Maragos and 
McCormick, 2000; Tangni et al., 2010; Xu et al., 2010). In other words, the discrepancies of 
the assay sensitivities to DON, 3-ADON and 15-ADON are so narrow that it is allowed to 
utilize the novel MAb for simultaneous detection of the three mycotoxins. As a result, the 
“total” DON content can be rapidly estimated in one assay and an overall health risk of DON 
exposure for the consumers can be assessed. The broad-selectivity of this MAb was probably 
due to the involved strategy of heterologous screening for hybridomas instead of the 
homologous one. Previous researches (Liu et al., 2010; Muldoon et al., 2000; Wang et al., 
2010) also indicated that application of this screening strategy increased the likelihood of 
isolating hybridomas secreting very broad-specific MAbs.  
Note that when comparing target analytes to analogues with different molecular weight 
(MW), cross-reactivity values calculated from units of mole per volume should be more 
accurate than those from units of weight per volume (though the latters are often used)(Xu et 
al., 2009), since cross-reactivity is a structure-related phenomenon in antibody-antigen 
binding. Generally, the gaps between CR and CRmolar values would not be too big, except that 
the antibody is broad-specific and shows high affinity to the analogue whose MW has a very 
significant deviation from that of the target analyte. Herein, as for the cross-reactivity of MAb 
13H1 to HT-2 toxin, the usual CR was 187%, while the CRmolar increased up to 268%. Also as 
described in a few references (Ruprich and Ostrý, 2008; Tangni et al., 2010), some DON-
ELISA tests displayed very high cross-reactivity to the masked form DON-3-G and the 
corresponding CRmolar values must be much larger than the normal CR values. Hence, we 
suggest that evaluation of the cross-reactivity of a broad-specific antibody should be based on 
the CRmolar values as far as possible. Certainly, CR data obtained in the current work can be 
somewhat different from the values declared later in the future application studies (because of 
various assay formats, sample matrixes and so on), but the general tendency should be similar. 
4. Conclusion 
In this study, two new types of anti-DON MAbs have been developed by heterologous 
screening of hybridomas, and this screening strategy appears to be an efficient approach for 
selecting hybridomas of interest. The superior MAb 10H10 has relatively similar affinity to 
DON, 3-ADON and 15-ADON, with IC50 values of 22, 15 and 34 ng/mL, respectively. This 
is, so far, the first broad-specific MAb against DON and its two acetylated forms, which can 
be used for simultaneous monitoring of the three mycotoxins. Thus, it would be further 
applied to different kinds of DON-related immunoassays, or immunoaffinity columns for 
sample clean-up before chromatographic analysis. 
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